The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.

doi:10.1038/s41467-022-28848-x

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.

Nature communications - 18 Mar 2022

Rosen Ezra Y, Won Helen H, Zheng Youyun, Cocco Emiliano, Selcuklu Duygu, Gong Yixiao, Friedman Noah D, de Bruijn Ino, Sumer Onur, Bielski Craig M, Savin Casey, Bourque Caitlin, Falcon Christina, Clarke Nikeysha, Jing Xiaohong, Meng Fanli, Zimel Catherine, Shifman Sophie, Kittane Srushti, Wu Fan, Ladanyi Marc, Ebata Kevin, Kherani Jennifer, Brandhuber Barbara J, Fagin James, Sherman Eric J, Rekhtman Natasha, Berger Michael F, Scaltriti Maurizio, Hyman David M, Taylor Barry S, Drilon Alexander

Abstract excerpt

The efficacy of the highly selective RET inhibitor selpercatinib is now established in RET-driven cancers, and we sought to characterize the molecular determinants of response and resistance. We find that the pre-treatment genomic landscape does not shape the variability of treatment response except for rare instances of RAS-mediated primary resistance. By contrast, acquired selpercatinib resistance is driven by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung

Share to Lung Cancer Treatments and Mutations

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins c-ret

Share to RNA modifications and cancer

Share to Thyroid Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 35304457
DOI: 10.1038/s41467-022-28848-x
PMCID: PMC8933489

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.PMID 35304457Read ↗

An early look at selective RET inhibitor resistance: new challenges and opportunities.Semantic proximity Read ↗

Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.Semantic proximity Read ↗

Mechanisms of resistance to RET-directed therapiesSemantic proximity Read ↗

Combination of Selpercatinib and Trametinib Overcomes Resistance to RET Inhibitors in RET-Mutant Medullary Thyroid Carcinoma.Semantic proximity Read ↗

RET Signaling Pathway in Human Cancer: Oncogenic Mechanisms, Selective Inhibitors, and Emerging Resistance Strategies.Semantic proximity Read ↗

Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion–Positive Lung Cancer by Combining Selpercatinib with CrizotinibSemantic proximity Read ↗

Targeting RET alterations in cancer: Recent progress and future directions.Semantic proximity Read ↗

Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes.Semantic proximity Read ↗

Modeling acquired TKI resistance and effective combination therapeutic strategies in murine RET+ lung adenocarcinomaSemantic proximity Read ↗

Targeting RET alterations in non-small cell lung cancer.Semantic proximity Read ↗

Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer.Semantic proximity Read ↗

Progress and challenges in RET-targeted cancer therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.